Cargando…
Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy
Recently, fibroblast activation protein (FAP), an overexpressed transmembrane protein of activated fibroblast in pulmonary fibrosis, has been considered as the new target for diagnosing and treating pulmonary fibrosis. In this work, mesoporous polydopamine (MPDA), which is facile prepared and easily...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363109/ https://www.ncbi.nlm.nih.gov/pubmed/35957641 http://dx.doi.org/10.3389/fbioe.2022.920766 |
_version_ | 1784764855969906688 |
---|---|
author | Fang, Qi Liu, Shaoyu Cui, Jiangyu Zhao, Ruiyue Han, Qian Hou, Peng Li, Youcai Lv, Jie Zhang, Xiaoyao Luo, Qun Wang, Xinlu |
author_facet | Fang, Qi Liu, Shaoyu Cui, Jiangyu Zhao, Ruiyue Han, Qian Hou, Peng Li, Youcai Lv, Jie Zhang, Xiaoyao Luo, Qun Wang, Xinlu |
author_sort | Fang, Qi |
collection | PubMed |
description | Recently, fibroblast activation protein (FAP), an overexpressed transmembrane protein of activated fibroblast in pulmonary fibrosis, has been considered as the new target for diagnosing and treating pulmonary fibrosis. In this work, mesoporous polydopamine (MPDA), which is facile prepared and easily modified, is developed as a carrier to load antifibrosis drug pirfenidone (PFD) and linking FAP inhibitor (FAPI) to realize lesion-targeted drug delivery for pulmonary fibrosis therapy. We have found that PFD@MPDA-FAPI is well biocompatible and with good properties of antifibrosis, when ICG labels MPDA-FAPI, the accumulation of the nanodrug at the fibrosis lung in vivo can be observed by NIR imaging, and the antifibrosis properties of PFD@MPDA-FAPI in vivo were also better than those of pure PFD and PFD@MPDA; therefore, the easily produced and biocompatible nanodrug PFD@MPDA-FAPI developed in this study is promising for further clinical translations in pulmonary fibrosis antifibrosis therapy. |
format | Online Article Text |
id | pubmed-9363109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93631092022-08-10 Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy Fang, Qi Liu, Shaoyu Cui, Jiangyu Zhao, Ruiyue Han, Qian Hou, Peng Li, Youcai Lv, Jie Zhang, Xiaoyao Luo, Qun Wang, Xinlu Front Bioeng Biotechnol Bioengineering and Biotechnology Recently, fibroblast activation protein (FAP), an overexpressed transmembrane protein of activated fibroblast in pulmonary fibrosis, has been considered as the new target for diagnosing and treating pulmonary fibrosis. In this work, mesoporous polydopamine (MPDA), which is facile prepared and easily modified, is developed as a carrier to load antifibrosis drug pirfenidone (PFD) and linking FAP inhibitor (FAPI) to realize lesion-targeted drug delivery for pulmonary fibrosis therapy. We have found that PFD@MPDA-FAPI is well biocompatible and with good properties of antifibrosis, when ICG labels MPDA-FAPI, the accumulation of the nanodrug at the fibrosis lung in vivo can be observed by NIR imaging, and the antifibrosis properties of PFD@MPDA-FAPI in vivo were also better than those of pure PFD and PFD@MPDA; therefore, the easily produced and biocompatible nanodrug PFD@MPDA-FAPI developed in this study is promising for further clinical translations in pulmonary fibrosis antifibrosis therapy. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9363109/ /pubmed/35957641 http://dx.doi.org/10.3389/fbioe.2022.920766 Text en Copyright © 2022 Fang, Liu, Cui, Zhao, Han, Hou, Li, Lv, Zhang, Luo and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Fang, Qi Liu, Shaoyu Cui, Jiangyu Zhao, Ruiyue Han, Qian Hou, Peng Li, Youcai Lv, Jie Zhang, Xiaoyao Luo, Qun Wang, Xinlu Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy |
title | Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy |
title_full | Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy |
title_fullStr | Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy |
title_full_unstemmed | Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy |
title_short | Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy |
title_sort | mesoporous polydopamine loaded pirfenidone target to fibroblast activation protein for pulmonary fibrosis therapy |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363109/ https://www.ncbi.nlm.nih.gov/pubmed/35957641 http://dx.doi.org/10.3389/fbioe.2022.920766 |
work_keys_str_mv | AT fangqi mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy AT liushaoyu mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy AT cuijiangyu mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy AT zhaoruiyue mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy AT hanqian mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy AT houpeng mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy AT liyoucai mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy AT lvjie mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy AT zhangxiaoyao mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy AT luoqun mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy AT wangxinlu mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy |